Donor Lymphocyte Infusions

BIOLOGICAL2 trials

Sponsors

Heinrich-Heine University, Duesseldorf, Groupe Francophone des Myelodysplasies

Conditions

AMLLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMDSMyelodysplastic Syndromes

Phase 2

Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT

CompletedNCT02472691

Heinrich-Heine University, DuesseldorfLeukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes

Start: 2015-05-31End: 2020-04-23Updated: 2020-05-28

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

CompletedNCT04857645

Groupe Francophone des MyelodysplasiesAML, MDS

Start: 2021-06-22End: 2025-04-22Updated: 2025-05-14

Related Papers

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.

2025-08-07

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial

Haematologica2023-06-0118 citations

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection

HemaSphere2021-02-1032 citations